Mingyue Zhou
Research Subjects
Mingyue Zhou has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Derek E. Piper
Structural Biology, Amgen Inc., 1120 Veterans Blvd., South San Francisco, CA 94080, United States
2 shared publicationsPreston Fordstrom
Metabolic Disorders, Amgen Inc., 1120 Veterans Blvd., South San Francisco, CA 94080, United States
2 shared publicationsAndrew Gates
‖Therapeutic Discovery, Amgen Inc., Burnaby, British Columbia V5A 1V7, Canada
1 shared publicationArtem A. Shkumatov
Comparative Biology and Safety Sciences, Amgen Research, South San Francisco, CA USA
1 shared publicationBrandon L. Ason
Cardiometabolic Disorders Therapeutic Area, Amgen Research, South San Francisco, CA USA
1 shared publicationCaroline Tao
Cardiometabolic Disorders Therapeutic Area, Amgen Research, South San Francisco, CA USA
1 shared publication
Latest Publications
- Open Access
- 16 January 2019
- Published by Springer Nature in Communications Biology
- Vol. 2 (1) , 1-10
Stigmasterol accumulation causes cardiac injury and promotes mortality
Cardiovascular disease is expected to remain the leading cause of death worldwide despite the introduction of proprotein convertase subtilisin/kexin type 9 inhibitors that effectively control cholesterol. Identifying residual risk factors for cardiovascular disease remains an important step for preventing and clinically managing the disease. Here we report cardiac injury and increased mortality occurring despite a 50% reduction in plasma cholesterol in a mouse model of phytosterolemia, a disease characterized by elevated levels of dietary plant sterols in the blood. Our studies show accumulation of stigmasterol, one of phytosterol species, leads to left ventricle dysfunction, cardiac interstitial fibrosis and macrophage infiltration without atherosclerosis, and increased mortality. A pharmacological inhibitor of sterol absorption prevents cardiac fibrogenesis. We propose that the pathological mechanism linking clinical sitosterolemia to the cardiovascular outcomes primarily involves phytosterols-induced cardiac fibrosis rather than cholesterol-driven atherosclerosis. Our studies suggest stigmasterol is a potent and independent risk factor for cardiovascular disease.
- 16 January 2019
- Published by Springer Nature in Communications Biology
- Vol. 2 (1) , 1-10
Open AccessStigmasterol accumulation causes cardiac injury and promotes mortality
Cardiovascular disease is expected to remain the leading cause of death worldwide despite the introduction of proprotein convertase subtilisin/kexin type 9 inhibitors that effectively control cholesterol. Identifying residual risk factors for cardiovascular disease remains an important step for preventing and clinically managing the disease. Here we report cardiac injury and increased mortality occurring despite a 50% reduction in plasma cholesterol in a mouse model of phytosterolemia, a disease characterized by elevated levels of dietary plant sterols in the blood. Our studies show accumulation of stigmasterol, one of phytosterol species, leads to left ventricle dysfunction, cardiac interstitial fibrosis and macrophage infiltration without atherosclerosis, and increased mortality. A pharmacological inhibitor of sterol absorption prevents cardiac fibrogenesis. We propose that the pathological mechanism linking clinical sitosterolemia to the cardiovascular outcomes primarily involves phytosterols-induced cardiac fibrosis rather than cholesterol-driven atherosclerosis. Our studies suggest stigmasterol is a potent and independent risk factor for cardiovascular disease.
- 1 September 2016
- Published by Elsevier in Protein Expression and Purification
- Vol. 125, 1-6
BacMam production of active recombinant lecithin–cholesterol acyltransferase: Expression, purification and characterization
- 1 September 2016
- Published by Elsevier in Protein Expression and Purification
- Vol. 125, 1-6
BacMam production of active recombinant lecithin–cholesterol acyltransferase: Expression, purification and characterization
- Open Access
- 1 February 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (6) , 2799-2811
Agonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism
- 1 February 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (6) , 2799-2811
Open AccessAgonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism